Selected article for: "acute respiratory syndrome and lung antiviral"
Author: Ko, Meehyun; Jeon, Sangeun; Ryu, Wang‐Shick; Kim, Seungtaek
Title: Comparative analysis of antiviral efficacy of FDA‐approved drugs against SARS‐CoV‐2 in human lung cells
  • Cord-id: fbddxbhd
  • Document date: 2020_8_16
    • ID: fbddxbhd
    Snippet: Drug repositioning represents an effective way to control the current COVID‐19 pandemic. Previously, we identified 24 FDA‐approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamo
    Document: Drug repositioning represents an effective way to control the current COVID‐19 pandemic. Previously, we identified 24 FDA‐approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC(50) = 0.0022 µM).

    Search related documents:
    Co phrase search for related documents
    • acute respiratory distress syndrome and lopinavir chloroquine hydroxy: 1
    • acute respiratory distress syndrome and low metabolic: 1, 2